Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

BACKGROUND: Data are limited regarding the use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed by maintenance as initial treatment in patients with high-grade serous ovarian carcinoma. METHODS: In an international, phase...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:N Engl J Med
Auteurs principaux: Coleman, Robert L., Fleming, Gini F., Brady, Mark F., Swisher, Elizabeth M., Steffensen, Karina D., Friedlander, Michael, Okamoto, Aikou, Moore, Kathleen N., Ben-Baruch, Noa Efrat, Werner, Theresa L., Cloven, Noelle G., Oaknin, Ana, DiSilvestro, Paul A., Morgan, Mark A., Nam, Joo-Hyun, Leath, Charles A., Nicum, Shibani, Hagemann, Andrea R., Littell, Ramey D., Cella, David, Baron-Hay, Sally, Garcia-Donas, Jesus, Mizuno, Mika, Bell-McGuinn, Katherine, Sullivan, Danielle M., Bach, Bruce A., Bhattacharya, Sudipta, Ratajczak, Christine K., Ansell, Peter J., Dinh, Minh H., Aghajanian, Carol, Bookman, Michael A.
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6941439/
https://ncbi.nlm.nih.gov/pubmed/31562800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1909707
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires